BridgeMD
Prevention study for Microalbuminuria
Official title New Taipei City 888 Digital Medical AI Platform for Prevention and Care of the Three Highs and Cardio-Renal-Vascular Diseases
ClinicalTrials.gov ID: NCT07588256
What this study is testing
- What it's testing
- Non-communicable diseases (NCDs), or chronic diseases, are a major public health burden globally and in Taiwan, and control of the "three highs" (hypertension, dyslipidemia, and hyperglycemia) is a national priority. Nearly half of the 10 leading causes of death in Taiwan are directly or indirectly related to atherosclerotic cardiovascular disease (ASCVD), for which hypertension, dyslipidemia, and abnormal blood glucose are the major risk factors.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- I.T-888-DIGICARE： Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive)...
- Hypertension
- With or without treatment, and meeting one of the following:
- Office blood pressure: two consecutive measurements \>130/80 mmHg
- Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of the weekly measurements exceeding this threshold
You likely can't join if
- I. T-888-DIGICARE
- Symptomatic heart failure (New York Heart Association functional class II-IV)
- End-stage renal disease requiring long-term dialysis
- Pregnant women or those planning pregnancy II. DREAM-G:
- Life expectancy \<1 year
- End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care
See the full eligibility criteria
- I.T-888-DIGICARE： Eligible participants must meet the definition of hypertension and at least one of the following chronic (non-hypertensive) conditions:
- Hypertension
- With or without treatment, and meeting one of the following:
- Office blood pressure: two consecutive measurements \>130/80 mmHg
- Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of the weekly measurements exceeding this threshold
- Hyperlipidemia
- With or without treatment, and
- LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD)
- Diabetes Mellitus
- With or without treatment, and
- HbA1c \>6.5%
- Chronic Kidney Disease (CKD)
- Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and
- Urine albumin-to-creatinine ratio (UACR) \>30 mg/g
- Atherosclerotic Cardiovascular Disease (ASCVD):
- Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology II. DREAM-G:
- Hypertension
- With or without treatment, and meeting one of the following:
- Office blood pressure: two consecutive measurements \>130/80 mmHg
- Home blood pressure: weekly average (morning/evening) \>130/80 mmHg, or more than half of weekly measurements exceeding this threshold
- Hyperlipidemia
- With or without treatment, and
- LDL-C \>100 mg/dL (or \>70 mg/dL in patients with diabetes or established ASCVD)
- Diabetes Mellitus
- With or without treatment, and
- HbA1c \>6.5%
- Chronic Kidney Disease (CKD)
- Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², and
- Measurable urinary microalbumin-to-creatinine ratio
- Atherosclerotic Cardiovascular Disease (ASCVD):
- Including coronary artery disease, cerebrovascular disease, peripheral arterial disease, or aortic pathology Participants must meet at least one of the above chronic disease conditions and:
- Untreated Hypertension:
- Morning home blood pressure (HBP) \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg,
- Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg
- Treated Hypertension:
- Morning home blood pressure \>130/80 mmHg: weekly average (≥4 days) \>130/80 mmHg,
- Or more than half of morning HBP measurements (≥4 days per week) \>130/80 mmHg
- Average home blood pressure ≤130/80 mmHg (used to determine treatment strategy)
- I. T-888-DIGICARE
- Symptomatic heart failure (New York Heart Association functional class II-IV)
- End-stage renal disease requiring long-term dialysis
- Pregnant women or those planning pregnancy II. DREAM-G:
- Life expectancy \<1 year
- End-stage renal disease (ESRD) requiring regular renal replacement therapy, including dialysis, kidney transplantation, or palliative care
- Severe liver cirrhosis
- Malignancy under active treatment
The study team makes the final eligibility decision.
Where it's taking place
- New Taipei City, Taiwan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Taipei City, Taiwan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.